Could a Long-Acting Prodrug of SN-38 be Efficacious in Sacituzumab Govitecan-Resistant Tumors?
© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply..
We previously proposed that sacituzumab govitecan (SG, Trodelvy®) likely acts as a simple prodrug of systemic SN-38 as well as an antibody drug conjugate (ADC). In the present commentary, we assess whether a long-acting SN-38 prodrug, such as PLX038, might be efficacious in SG-resistant patients. We first describe possible mechanisms of action of SG, with new insights on pharmacokinetics and TROP2 receptor occupancy. We argue that SG is not an optimal conventional ADC and that the amount of systemic SN-38 spontaneously hydrolyzed from the ADC is so high it must have activity. Then, we describe the concept of time-over-target as related to the pharmacology of SG and PLX038 as SN-38 prodrugs. To be clear, we are not in any way suggesting that PLX038 or any SN-38 prodrug is superior to SG as an anticancer agent. Clearly, SG has the benefit over antigen-independent SN-38 prodrugs in that it targets cells with the TROP2 receptor. However, we surmise that PLX038 should be a more efficacious and less toxic prodrug of systemic SN-38 than SG. Finally, we suggest possible mechanisms of SG resistance and how PLX038 might perform in the context of each. Taken together, we argue that-contrary to many opinions-SG does not exclusively act as a conventional ADC, and propose that PLX038 may be efficacious in some settings of SG-resistance.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy - 38(2024), 2 vom: 01. März, Seite 171-176 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Santi, Daniel V [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7673326042 |
|---|
| Anmerkungen: |
Date Completed 06.03.2024 Date Revised 07.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s40259-024-00643-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367270420 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367270420 | ||
| 003 | DE-627 | ||
| 005 | 20240307232216.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240118s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40259-024-00643-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1319.xml |
| 035 | |a (DE-627)NLM367270420 | ||
| 035 | |a (NLM)38236523 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Santi, Daniel V |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Could a Long-Acting Prodrug of SN-38 be Efficacious in Sacituzumab Govitecan-Resistant Tumors? |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.03.2024 | ||
| 500 | |a Date Revised 07.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply. | ||
| 520 | |a We previously proposed that sacituzumab govitecan (SG, Trodelvy®) likely acts as a simple prodrug of systemic SN-38 as well as an antibody drug conjugate (ADC). In the present commentary, we assess whether a long-acting SN-38 prodrug, such as PLX038, might be efficacious in SG-resistant patients. We first describe possible mechanisms of action of SG, with new insights on pharmacokinetics and TROP2 receptor occupancy. We argue that SG is not an optimal conventional ADC and that the amount of systemic SN-38 spontaneously hydrolyzed from the ADC is so high it must have activity. Then, we describe the concept of time-over-target as related to the pharmacology of SG and PLX038 as SN-38 prodrugs. To be clear, we are not in any way suggesting that PLX038 or any SN-38 prodrug is superior to SG as an anticancer agent. Clearly, SG has the benefit over antigen-independent SN-38 prodrugs in that it targets cells with the TROP2 receptor. However, we surmise that PLX038 should be a more efficacious and less toxic prodrug of systemic SN-38 than SG. Finally, we suggest possible mechanisms of SG resistance and how PLX038 might perform in the context of each. Taken together, we argue that-contrary to many opinions-SG does not exclusively act as a conventional ADC, and propose that PLX038 may be efficacious in some settings of SG-resistance | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a sacituzumab govitecan |2 NLM | |
| 650 | 7 | |a M9BYU8XDQ6 |2 NLM | |
| 650 | 7 | |a Irinotecan |2 NLM | |
| 650 | 7 | |a 7673326042 |2 NLM | |
| 650 | 7 | |a Prodrugs |2 NLM | |
| 650 | 7 | |a Antigens, Neoplasm |2 NLM | |
| 650 | 7 | |a Immunoconjugates |2 NLM | |
| 650 | 7 | |a Camptothecin |2 NLM | |
| 650 | 7 | |a XT3Z54Z28A |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 700 | 1 | |a Ashley, Gary W |e verfasserin |4 aut | |
| 700 | 1 | |a Cabel, Luc |e verfasserin |4 aut | |
| 700 | 1 | |a Bidard, Francois-Clement |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy |d 1997 |g 38(2024), 2 vom: 01. März, Seite 171-176 |w (DE-627)NLM096446870 |x 1179-190X |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2024 |g number:2 |g day:01 |g month:03 |g pages:171-176 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s40259-024-00643-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2024 |e 2 |b 01 |c 03 |h 171-176 | ||